South Dakota confirms 2nd case of measles in 2025
The DOH sent the announcement out at 4:48 p.m. on Friday, informing the public that there was potential of a measles exposure at two locations in Pennington County.
21-year-old Brookings man arrested for rape of minor
These were the Sam's Club at 925 Eglin St in Rapid City on June 1 from noon to 6:00 p.m., and the Dakota Premier Medical Clinic at 2006 Mt Rushmore Rd in Rapid City on June 2 from 11:15 a.m. to 3:45 p.m.
The DOH is advising any person who visited those locations during the mentioned time frames that they may have been exposed to measles, and are asked to self-monitor for symptoms of measles for 21 days after the exposure date.
Measles symptoms appear in two stages. In the first stage, the individual may have a runny nose, cough, and a slight fever. The eyes may become reddened and sensitive to light while the fever consistently rises each day. The second stage begins on the third to seventh day of symptoms and consists of a temperature of 103-105°F, and a red blotchy rash lasting for four to seven days. The rash usually begins on the face and then spreads down to the trunk and out to the arms and legs.
Information from the DOH
'We are sharing this information to help individuals who may have been exposed take steps to protect their health,' said State Epidemiologist Joshua Clayton. 'Any South Dakotan who lack immunity from vaccination or past infection can get the MMR vaccine to prevent measles infection and its complications.'
South Dakota's first measles case of 2025 was reported on June 2, and was identified in a man in Meade County who developed the infection after traveling internationally.
That man had visited the following locations, where people who may have been exposed are also asked to self-monitor:
Rapid City Medical Center Urgent Care waiting room (2820 Mt Rushmore Road, Rapid City, SD
May 28, 2025, from 7:15 am to 10 am MT
Monument Health Sturgis Urgent Care waiting room (2140 Junction Ave, Sturgis, SD)
May 29, 2025, from 9:45 am to 3 pm MT
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
13 hours ago
- NBC News
1 dead, 22 sick from Legionnaires' cluster in Harlem, health officials say
A person has died and nearly two dozen people have fallen ill as part of a Legionnaires' cluster in Harlem, according to city health officials. The disease was initially detected on on July 25; since that time, one person has died and 22 have been diagnosed, the New York City Health Department said Wednesday. There were no details immediately available regarding the person who died as a result of the illness. Legionnaire's, a type of pneumonia, is caused by the bacteria Legionella, which grows in warm water. The cases from the cluster have been found in five Harlem ZIP codes: 10027, 10030, 10035, 10037 and 10039, along with the bordering communities, according to health officials. All cooling towers that are operating in the impacted area have been sampled, and the Health Department has told owners of buildings where positive results were found to initiate remediation within a day. Those who have been in the impacted area since late July and have been experiencing flu-like symptoms, fever, cough or difficulty breathing should seek medial attention immediately, according to the Health Department. Legionnaires' disease is not transmitted from person to person, and is treatable with antibiotics. It spread by breathing in water vapor containing the Legionella bacteria. Conditions for the bacteria to grow are favorable in things like cooling towers, whirlpool spas, hot tubs, humidifiers, hot water tanks and condensers of large air-conditioning systems. An investigation is ongoing. Individuals at higher risk include those 50 years old and older, cigarette smokers, and people with chronic lung disease or compromised immune systems. People living or working in the area who are experiencing these symptoms should seek medical attention with a primary care provider or seek urgent care, officials say. In 2022, at least five people died of Legionnaires' disease over the summer at a Manhattan nursing home in the city's worst outbreak, in terms of total cases, since a cooling tower in the Bronx was blamed for an infection that caused 16 deaths. Usually, about 200 to 700 people are diagnosed each year, official health data show. What is Legionnaires' disease? Legionnaires is a type of pneumonia, or a lung infection, the state DOH said. The legionella bacteria can also lead to a milder illness called Pontiac fever, which resembles flu-like symptoms. How does it spread? Legionella bacteria spread when someone inhales tiny droplets of contaminated water, commonly found in hot tubs, industrial air conditioning systems, decorative fountains, plumbing systems and even drinking water. Outbreaks often occur in large and complex water systems found in places like hotels, hospitals, and cruise ships. The bacteria can also survive and spread in soil, occasionally causing infections when people garden using contaminated soil. However, in most cases, people do not transmit Legionnaires' disease or Pontiac fever to others. What are the symptoms? Symptoms of Legionnaires disease typically appear between two to 10 days after exposure to the bacteria and can include: Headache Muscle aches Shortness of breath Cough Fever The New Jersey Department of Health noted that the symptoms can be similar to those of COVID-19 and other respiratory illnesses like the flu. Only tests ordered by a doctor can confirm a diagnosis. Who is at higher risk? Those most susceptible to Legionnaires' disease include adults over 50, individuals with weakened immune systems or chronic conditions, and smokers. It is rarer for healthy people who are exposed to the legionella bacteria to develop Legionnaires' disease. Can it be treated? Antibiotics are used to treat Legionnaires' disease, though it often requires hospitalization. Anyone suspecting exposure to Legionella or experiencing symptoms of Legionella disease or pneumonia should promptly contact a doctor. It's important to mention any exposure to Legionella, hot tub use, recent travels, or hospital stays in the past two weeks.
The Hill
19 hours ago
- The Hill
Canada has three times as many measles cases as US
Canada has had three times as many measles cases as the U.S. this year, according to Canadian government and Centers for Disease Control and Prevention (CDC) data. Canada has faced 4,206 measles cases this year, according to a government website, with 1,450 in Alberta, 2,301 in Ontario and 140 in British Columbia. However, the government also said 3,878 of the total cases were confirmed. According to the CDC, there have been 1,333 confirmed cases in the U.S. in 2025, with Texas having the highest number of cases out of all of the 50 states at over 700. The current U.S. government, especially Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has been facing scrutiny over its approach to vaccination, with Kennedy previously expressing vaccine skepticism. In April, Kennedy touted the measles, mumps and rubella (MMR) vaccine as the 'most effective' method to stop measles spreading amid a visit to Texas with the family of an 8-year-old girl who was killed by the disease. 'The most effective way to prevent the spread of measles is the MMR vaccine,' Kennedy wrote in a post on the social platform X at the time. 'I've spoken to Governor Abbott, and I've offered HHS' continued support.'
Newsweek
a day ago
- Newsweek
You Could Receive COVID Vaccines via Dental Floss in Future
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Vaccines given via dental floss could one day allow people to immunize themselves from COVID in the comfort of their own homes without having to use needles. This is the finding of North Carolina (NC) State University researchers who have demonstrated the new delivery method in an animal model—introducing a flu vaccine via the tissue between the teeth and gums. The novel approach has potential for broad application, the team says. "We expect the approach to work with COVID vaccine that uses mRNA, hepatitis and tetanus since they use subunit proteins as antigens, and other vaccines that use inactivated or attenuated viruses as antigens (such as MMR vaccine)," paper author and NC State nanomedicine professor Harvinder Singh Gill told Newsweek. "In essence through proper formulation of the coating, the approach should work with any vaccine." Woman holding a dental floss pick in her teeth. Woman holding a dental floss pick in her teeth. AndreyPopov/Getty Images The researchers discovered the new method stimulates the production of antibodies in mucosal surfaces—the moist linings of various body cavities— like the nose and lungs. "Mucosal surfaces are important, because they are a source of entry for pathogens, such as influenza and COVID," Gill said in a statement. "However, if a vaccine is given by injection, antibodies are primarily produced in the bloodstream throughout the body, and relatively few antibodies are produced on mucosal surfaces. "But we know that when a vaccine is given via the mucosal surface, antibodies are stimulated not only in the bloodstream, but also on mucosal surfaces. "This improves the body's ability to prevent infection, because there is an additional line of antibody defense before a pathogen enters the body." A health worker injects vaccine into patient's arm for Covid-19. A health worker injects vaccine into patient's arm for Covid-19. wisely/Getty Images Something called the 'junctional epithelium'—a thin layer of tissue that lines the surface of body parts—also played an important role in the study. While most epithelial tissues include robust barriers designed to keep 'bad' things like viruses and dirt from entering your blood stream, the junctional epithelium lacks such a barrier. This allows the junctional epithelium to release immune cells to fight bacteria, typically found in saliva and between teeth and gums. Gill explained, "The idea to use the junctional epithelium came through a chance reading in the literature that the 'junctional epithelium' is 'highly permeable'. The Gill lab has been working to develop mucosal vaccines for almost 20 years." He said the words 'highly permeable' were "like nectar" to him and "sparked an aha moment" because the mucosal tissues such as those in the gut, lungs and reproductive services are 'highly impermeable', making vaccine delivery challenging. This left him excited to test the new method out. "To our knowledge no one has ever used the junctional epithelium nor the floss for vaccine delivery," Gill added. Two light microscope images representing the junctional epithelium. Two light microscope images representing the junctional epithelium. JOSE LUIS CALVO MARTIN & JOSE ENRIQUE GARCIA-To assess the viability of delivering vaccines through the junctional epithelium, the researchers applied the vaccine to unwaxed dental floss and then flossed the teeth of mice. They compared antibody production in mice that received a peptide flu vaccine "via flossing the junctional epithelium; via the nasal epithelium; or via placing vaccine on the mucosal tissue under the tongue." "We found that applying vaccine via the junctional epithelium produces far superior antibody response on mucosal surfaces than the current gold standard for vaccinating via the oral cavity, which involves placing vaccine under the tongue," paper author Rohan Ingrole, who was a Ph.D. student under Gill at Texas Tech University, said in a statement. "The flossing technique also provides comparable protection against flu virus as compared to the vaccine being given via the nasal epithelium." "This is extremely promising, because most vaccine formulations cannot be given via the nasal epithelium—the barrier features in that mucosal surface prevent efficient uptake of the vaccine," added Gill. "Intranasal delivery also has the potential to cause the vaccine to reach the brain, which can pose safety concerns. However, vaccination via the junctional epithelium offers no such risk. "For this experiment, we chose one of the few vaccine formulations that actually works for nasal delivery because we wanted to see how junctional epithelium delivery compared to the best-case scenario for nasal delivery." The researchers also tested whether the junctional epithelium delivery method worked for three other prominent classes of vaccines—proteins, inactivated viruses and mRNA (a type of single-stranded RNA involved in protein synthesis, RNA being a key molecule found in living cells and viruses). The delivery technique produced "robust antibody responses" in the bloodstream and across mucosal surfaces in all three. Evident at least in the animal model, it didn't matter whether food and water was consumed immediately flossing with the vaccine—the immune response was the same. The researchers acknowledged, however, the impracticality of asking people to hold vaccine-coated floss in their fingers. This led them to introduce a floss pick with a handle, just like the one you might use for removing plaque and food particles. They coated the floss with fluorescent food dye, recruited 27 study participants, explained the new floss-based vaccine concept and asked them to try to deposit the food dye in their epithelial junction with a floss pick. Roughly 60 percent of the dye was deposited in the gum pocket, suggesting the floss pick may be a practical vaccine delivery method to the epithelial junction, according to the researchers. "For accessibility the advantage is that the vaccine is coated as a solid and thus it can be more stable and may not need cold storage. A floss could be self-administered, is painless and may receive better acceptance as compared to shots," said Gill. While more research is needed before the innovative method could be considered for clinical use, the researchers think the positives could extend beyond the improved antibody response—from ease of administration and easing vaccine concerns about needles to a comparable price. The CDC recommends an updated 2024–2025 COVID-19 vaccine for most adults 18 and older, while parents of children aged six months to 17 years should discuss the benefits of vaccination with a healthcare provider. However, six in 10 Americans said they would probably not get an updated 2024–2025 COVID-19 vaccine, according to an October Pew Research Center survey. Concern about side effects and feeling that the updated vaccine is personally unnecessary were the top two reasons why people were reluctant—regardless of age, party, or race and ethnicity. A smaller share of those not planning to get an updated vaccine said a major reason why is that they generally don't get vaccines. Very few cited cost as a major reason, according to the survey. Some drawbacks of the potential floss-vaccine to consider include that it wouldn't work on infants and toddlers without teeth and whether it would work for people with gum disease or other oral infections. What about side effects? "This requires more study. The anticipation is that the side effects may not be any greater than conventional shots," said Gill. "Next, the approach should be tested on larger animals such as pigs. Additional engineering is also needed to improve upon the device itself so that it is more user friendly. In the long-term, our vision is that this could be a kit either used in the comfort of home, or a dentist's office, or pharmacies." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about vaccination? Let us know via health@ Reference Ingrole, R. S. J., Shakya, A. K., Joshi, G., Lee, C. H., Nesovic, L. D., Compans, R. W., & Gill, H. S. (2025). Floss-based vaccination targets the gingival sulcus for mucosal and systemic immunization. Nature Biomedical Engineering.
